Controversy regarding ACE inhibitors / ARBs in COVID-19.
作者信息
Soria Arcos Federico, Romero Puche Antonio, Vicente Vera Tomás
机构信息
Servicio de Cardiología, Hospital Santa Lucía, Cartagena, Murcia, Spain.
Servicio de Cardiología, Hospital Reina Sofía, Murcia, Spain.
出版信息
Rev Esp Cardiol (Engl Ed). 2020 Jun;73(6):516. doi: 10.1016/j.rec.2020.04.004. Epub 2020 Apr 15.
Abstract
摘要
相似文献
1
Controversy regarding ACE inhibitors / ARBs in COVID-19.关于血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂在2019冠状病毒病中的争议。
Rev Esp Cardiol (Engl Ed). 2020 Jun;73(6):516. doi: 10.1016/j.rec.2020.04.004. Epub 2020 Apr 15.
2
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients With Coronavirus Disease 2019: Friend or Foe?血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂在 2019 冠状病毒病患者中的应用：是敌是友？
Cardiol Rev. 2020 Jul/Aug;28(4):213-216. doi: 10.1097/CRD.0000000000000319.
3
COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.2019冠状病毒病与心血管疾病：我们已知的、我们自认为已知的以及我们需要了解的情况。
J Mol Cell Cardiol. 2020 Jul;144:12-14. doi: 10.1016/j.yjmcc.2020.04.026. Epub 2020 Apr 24.
4
The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies.SARS-CoV-2 的受体 ACE-2 在许多不同的细胞类型上表达：对基于 ACE 抑制剂和血管紧张素 II 受体阻滞剂的心血管治疗的影响。
Intern Emerg Med. 2020 Aug;15(5):759-766. doi: 10.1007/s11739-020-02364-6. Epub 2020 May 19.
5
The role of ACEIs/ARBs in COVID-19: Friend or foe?血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂在2019冠状病毒病中的作用：是友还是敌？
Med Hypotheses. 2020 Sep;142:109810. doi: 10.1016/j.mehy.2020.109810. Epub 2020 May 5.
6
SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对血管紧张素转换酶2（ACE2）的下调作用以及血管紧张素转换酶抑制剂（ACEIs）/血管紧张素Ⅱ受体阻滞剂（ARBs）的多效性作用
Hypertens Res. 2020 Sep;43(9):985-986. doi: 10.1038/s41440-020-0488-z. Epub 2020 Jun 10.
7
[ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].[血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂与冠状病毒引起的严重急性呼吸综合征]
G Ital Cardiol (Rome). 2020 May;21(5):321-327. doi: 10.1714/3343.33127.
8
Drugs and the renin-angiotensin system in covid-19.新冠病毒肺炎中的药物与肾素-血管紧张素系统
BMJ. 2020 Apr 2;369:m1313. doi: 10.1136/bmj.m1313.
9
Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.停止使用 ACEI 和 ARB 类药物对 COVID-19 患者的潜在有害影响。
Elife. 2020 Apr 6;9:e57278. doi: 10.7554/eLife.57278.
10
Considerations on the use of antihypertensive blockers of the renin-angiotensin system in adults and children in the face of the COVID-19 pandemic.关于在新冠疫情背景下成人和儿童使用肾素-血管紧张素系统降压阻滞剂的考量
Bol Med Hosp Infant Mex. 2020;77(5):274-281. doi: 10.24875/BMHIM.20000158.
引用本文的文献
1
Lisinopril increases lung ACE2 levels and SARS-CoV-2 viral load and decreases inflammation but not disease severity in experimental COVID-19.在实验性新冠肺炎中，赖诺普利可提高肺部血管紧张素转换酶2（ACE2）水平和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量，并减轻炎症，但不会降低疾病严重程度。
Front Pharmacol. 2024 Jul 12;15:1414406. doi: 10.3389/fphar.2024.1414406. eCollection 2024.
2
Design and study of bioisosteric analogues of the drug Molnupiravir as potential therapeutics against SARS-COV-2: an in silico approach.作为抗SARS-CoV-2潜在疗法的药物莫努匹韦生物电子等排类似物的设计与研究：一种计算机模拟方法
In Silico Pharmacol. 2023 Dec 2;12(1):1. doi: 10.1007/s40203-023-00171-3. eCollection 2024.
3
Role of the renin-angiotensin system in the development of COVID-19-associated neurological manifestations.肾素-血管紧张素系统在新型冠状病毒肺炎相关神经表现发展中的作用。
Front Cell Neurosci. 2022 Sep 16;16:977039. doi: 10.3389/fncel.2022.977039. eCollection 2022.
4
The effect of various compounds on the COVID mechanisms, from chemical to molecular aspects.各种化合物对 COVID 机制的影响，从化学到分子方面。
Biophys Chem. 2022 Sep;288:106824. doi: 10.1016/j.bpc.2022.106824. Epub 2022 May 12.
5
Effect of Underlying Cardiovascular Disease on the Prognosis of COVID-19 Patients; a Sex and Age-Dependent Analysis.潜在心血管疾病对COVID-19患者预后的影响；一项性别和年龄依赖性分析。
Arch Acad Emerg Med. 2021 Sep 30;9(1):e65. doi: 10.22037/aaem.v9i1.1363. eCollection 2021.
6
Integrating heterogeneous data to facilitate COVID-19 drug repurposing.整合异质数据以促进 COVID-19 药物再利用。
Drug Discov Today. 2022 Feb;27(2):558-566. doi: 10.1016/j.drudis.2021.10.002. Epub 2021 Oct 16.
7
Predictors of severity and development of critical illness of Egyptian COVID-19 patients: A multicenter study.埃及 COVID-19 患者重症和危重症发展的预测因素：一项多中心研究。
PLoS One. 2021 Sep 23;16(9):e0256203. doi: 10.1371/journal.pone.0256203. eCollection 2021.
8
Fulminant hepatic failure in a patient testing re-positive for SARS-CoV-2: a case report.一名新型冠状病毒肺炎核酸检测复阳患者的暴发性肝衰竭：病例报告
Int J Emerg Med. 2021 Apr 21;14(1):24. doi: 10.1186/s12245-021-00349-6.
9
COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge?新型冠状病毒肺炎与心血管后果：内皮功能障碍是最严峻的挑战吗？
Thromb Res. 2020 Dec;196:143-151. doi: 10.1016/j.thromres.2020.08.039. Epub 2020 Aug 27.
本文引用的文献
1
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.血管紧张素转换酶2（ACE2）作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体：分子机制与潜在治疗靶点
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
2
Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.新型冠状病毒在武汉持续爆发中的进化及其刺突蛋白对人类传播风险的建模。
Sci China Life Sci. 2020 Mar;63(3):457-460. doi: 10.1007/s11427-020-1637-5. Epub 2020 Jan 21.
3
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury.血管紧张素转换酶2（ACE2）在严重急性呼吸综合征冠状病毒诱导的肺损伤中的关键作用。
Nat Med. 2005 Aug;11(8):875-9. doi: 10.1038/nm1267. Epub 2005 Jul 10.
4
Angiotensin-converting enzyme 2 protects from severe acute lung failure.血管紧张素转换酶2可预防严重急性肺衰竭。
Nature. 2005 Jul 7;436(7047):112-6. doi: 10.1038/nature03712.
Zotero 插件